Recce Pharmaceuticals Ltd. announced the China National Intellectual Property Administration has formally granted Recce a new family two patent, Copolymer and Method for Treatment of Bacterial Infection, for its anti-infectives, with expiry in 2035. This is the final of Recce?s wholly-owned patents granted for family two, with the Company now patent-protected in all major pharmaceutical markets globally. The Chinese patent claims relate to RECCE 327 (R327) and RECCE 529 (R529), including their methods of manufacture, administration, and application to treat a broad range of common human infections.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.575 AUD | -3.36% | +4.55% | +7.48% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+7.48% | 77.79M | |
+51.63% | 796B | |
+41.51% | 628B | |
-5.10% | 358B | |
+19.90% | 331B | |
+9.95% | 301B | |
+17.66% | 244B | |
+3.39% | 228B | |
+10.75% | 214B | |
+6.99% | 165B |
- Stock Market
- Equities
- RCE Stock
- News Recce Pharmaceuticals Ltd
- Recce Pharmaceuticals Ltd Receives New Patent in China for RECCE Anti-Infectives from China National Intellectual Property Administration